3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
29
Ovarian Neoplasms
2
Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Locoregional Recurrence
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Granulosa cell tumor of the ovary
1
Endometrial Neoplasms
1
Carcinoma, Ductal
1
Breast Carcinoma In Situ
1
Anatomic Stage III Breast Cancer AJCC v8
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Carcinoma
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
12
Cisplatin
11
Specimen Handling
9
Bevacizumab
7
Brachytherapy
6
Platinum
5
Paclitaxel
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Human Papillomavirus DNA Tests
5
Colposcopy
5
Carboplatin
5
atezolizumab
4
Gemcitabine
4
Fulvestrant
4
Surveys and Questionnaires
3
Radiotherapy
3
Radiation Dose Hypofractionation
3
Radiation
3
Drug Therapy
3
Blood Specimen Collection
3
1,2-diaminocyclohexaneplatinum II citrate
3
tisotumab vedotin
2
palbociclib
2
lenvatinib
2
Topotecan
2
Restraint, Physical
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Magnetic Resonance Imaging
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
exemestane
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled